274 related articles for article (PubMed ID: 34621045)
1. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
Herzog SK; Fuqua SAW
Br J Cancer; 2022 Feb; 126(2):174-186. PubMed ID: 34621045
[TBL] [Abstract][Full Text] [Related]
2. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
3. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
4. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
5. ESR1 fusions and therapeutic resistance in metastatic breast cancer.
Nagy Z; Jeselsohn R
Front Oncol; 2022; 12():1037531. PubMed ID: 36686845
[TBL] [Abstract][Full Text] [Related]
6. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
7. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
Angus L; Beije N; Jager A; Martens JW; Sleijfer S
Cancer Treat Rev; 2017 Jan; 52():33-40. PubMed ID: 27886589
[TBL] [Abstract][Full Text] [Related]
8. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
Dustin D; Gu G; Beyer AR; Herzog SK; Edwards DG; Lin H; Gonzalez TL; Grimm SL; Coarfa C; Chan DW; Kim BJ; De La O JP; Ellis MJ; Liu D; Li S; Welm AL; Fuqua SAW
Br J Cancer; 2021 Jan; 124(1):191-206. PubMed ID: 33257837
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
10. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
11. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
12. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
Wu Y; Li Z; Lee AV; Oesterreich S; Luo B
Breast Cancer Res Treat; 2024 Jun; 205(2):371-386. PubMed ID: 38427312
[TBL] [Abstract][Full Text] [Related]
13. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
[TBL] [Abstract][Full Text] [Related]
14. ESR1 mutations in breast cancer.
Dustin D; Gu G; Fuqua SAW
Cancer; 2019 Nov; 125(21):3714-3728. PubMed ID: 31318440
[TBL] [Abstract][Full Text] [Related]
15. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM; Jeselsohn RM
Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
[TBL] [Abstract][Full Text] [Related]
16. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
17. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
[TBL] [Abstract][Full Text] [Related]
19. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
[TBL] [Abstract][Full Text] [Related]
20. Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.
Reinert T; Gonçalves R; Bines J
Curr Treat Options Oncol; 2018 Apr; 19(5):24. PubMed ID: 29666928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
